The transplant community, including patients and carers, physicians, scientists and health-care workers, has long benefited from the altruistic donations provided by sibling or unrelated volunteer individuals. It is, therefore, to our shame that it has taken over 40 years for a careful consideration of the rights of the donor to be fully informed of the nature of the research being undertaken in the transplant centre, to appear in the transplant literature. King and colleagues have given great thought to this matter and have concluded that when the donor is required to do more than simply provide cells for a straightforward transplant procedure or to provide data and/or material that will be used in an identifiable manner, the research protocol should be approved in the country of origin of both donor and patient, the donor should be fully informed and should have the right to refuse to participate. This seems entirely reasonable and, as the authors argue, in keeping with the spirit of the Helsinki agreement.
The practicalities, interpretation and implications of such a recommendation, however, are not so simple. The authors particularly cite the example of a donor being asked to provide more than the usual number of cells because, for instance, a technical procedure necessitates a larger than the usual collection. But this is commonplace. T-cell depletion by ex vivo positive or negative selection is well known to result in the loss of potential repopulating cells, non-myeloablative preparative regimens are based in part on the ability to infuse large numbers of CD34 þ cells and both strategies undoubtedly increase the risks of both graft failure and disease relapse, increasing the chance of a request for the provision of a second harvest and/or lymphocyte donations. Nonmyeloablative transplants have become the standard of care for several transplant indications, including myelodysplasia, myelofibrosis and low-grade lymphoproliferative disorders, yet, the donor centre is highly unlikely to know the nature of the conditioning regimen. Would this be considered a research protocol with respect to the donor or simply an inconvenience? If the patient was participating in a research protocol of myeloablative vs non-myeloablative conditioning, will the donor also be involved? The risk of inconsistency seems considerable.
We routinely collect data about the donor that are required for donor selection and we have long submitted these data to local, national and international registries where they are used for retrospective analyses with research intent. Furthermore, gradual improvements in donor selection have resulted from technical developments in HLA typing, and research into cytokine polymorphisms and KIR typing, to name but two, are providing valuable information as to the nature of allogeneic interactions and might translate into new therapeutic approaches. To date all these activities have been performed without donor's knowledge and informed consent; is this to change in the future? MSC promise to be the most effective therapy for steroid-resistant GVHD but will require a BM donation, an additional burden for those who have donated bloodderived stem cells. If the patient is treated on a compassionate use protocol or as seems more likely, MSC becomes a routine treatment, there will be no research protocol and therefore nothing that can be submitted to an ethics review board.
King and colleagues from the World Marrow Donor Association (WMDA) suggest that when a donor's data or tissue are used for research, the research protocol must be presented to and approved by the regulatory authorities in the country of residence of the donor. Those of us in Europe who have struggled with the administrative burden placed upon us by the requirements of the European Union Directive on Clinical Trials will read this with a feeling of impending dread. This is not, as they suggest, a simple matter of sending a protocol to a local ethics review board. Furthermore, the Directive is designed to prevent informal agreements that trials approved in one country may be used in another without passing through the national regulatory authorities. Cells are considered as investigational medicinal products in clinical trials in Europe and any trial requires Clinical Trial Authorization and Ethics Committee approval in every country involved in the study together with rigorously controlled agreements with every participating site and insurance of all participants. More than 20 different languages are spoken in the EU member states and many documents must be submitted in the local language. Since the implementation of the Directive in most member states in 2003, the numbers of academic investigator-led international multicentre studies have declined by 30% and the time for approval has increased similarly. A requirement to include the countries that might provide a donor (perhaps only one) in addition to those where the patients reside is not trivial. And who will champion the protocol, translate the documents, attend the regulatory meetings, answer queries and comply with pharmacovigilance requirements in the donor's country? The donor centre has little to gain from the successful completion of a local study performed in another nation and the burden of work may simply prove prohibitive. In the current regulatory environment in Europe, one thing is certain, this will not be quick! And as every transplant worker knows, speed is often essential in unrelated transplantation.
The unfortunate outcome of the laudable considerations of the Clinical and Ethics Working Groups of the WMDA is that research protocols involving unrelated donors may suffer the misfortune of many other international studies in Europe and simply not take place. Pressure is being brought to bear upon the European Commission to introduce small but important changes in the Directive that will harmonize submissions and accelerate the process for approval, but success is not guaranteed. So can we think of another approach? The donors have already proven themselves to be the most altruistic of individuals and it is hard to imagine that any one of them would wish to impede research. Requests for second donations are rarely refused. In addition, every donor and patient is already a research subject in that anonymized, but readily identifiable, data have been collected in the centre and submitted to the transplant registries for many years.
The donor centres give potential donors' information about the harvest process and the risks involved. Undoubtedly, they talk about the possibility of a second donation. But is this presented as a 'possibility' or a 'probability' or a 'virtual certainty'? Perhaps donors should be explicitly informed of the implicit research nature of unrelated donor transplantation? If, for instance, we provided donors with the current chance that they will be asked to donate additional tissue at a later date and explained that this figure is constantly increasing with modern approaches to transplant, would this circumvent the cumbersome nature of regulatory approval? At least one donor registry already explains to donors that a small fraction of their cells might be used in a laboratory for research protocols that have been approved by the ethics committee at the transplant or donor centre and seeks their consent for this. If this approach were to be extended to all registries, would many of the donors require detailed information about each study and/or withhold consent?
There is only one way to find out and this is to engage donors in these conversations.
An analogous situation has arisen with the increasing engagement of patient interest groups in the discussions around the EU Clinical Trials Directive. The regulators understandably wish to ensure trial quality and patient safety but interestingly, the patients are the first to admit that the use of new drugs or devices carries risks and to remind us that they are prepared to take reasonable risks if these risks are fully explained and they deem the risk worth taking. It is more than time that the donors' voices were heard as only they can tell us the level of information which they will require to help them in deciding whether to participate. The donor registries must further develop advisory groups comprised of their donors and support a global discussion. An appropriate lead might be provided by the newly formed donor centre committee of the Worldwide Network for Blood and Marrow Transplantation. SCT has been an excellent example of global collaboration in terms of comprehensive registries, enabling data collection and analysis, research activity resulting in changes and improvements in clinical practice and the availability and transport of literally unique tissue around the world. This international effort should now involve our donors.
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